Lymph node and spleen sarcoidosis
ICD-10 D86.1 · ICD-11 4B20.1

Treatment of Lymph Node and Spleen Sarcoidosis When Corticosteroids Are Not Enough

Lymph node and spleen sarcoidosis (ICD-10 D86.1 / ICD-11 4B20.1) is managed initially with corticosteroids. When the response to prednisone is inadequate or corticosteroid toxicity limits its use, a steroid-sparing agent is considered as part of the treatment approach.

Clinical Situation

This protocol addresses patients with lymph node and spleen sarcoidosis who have not achieved a satisfactory response to corticosteroids alone, or in whom ongoing corticosteroid exposure carries unacceptable risk. In these cases, the addition of a steroid-sparing cytotoxic agent to the existing regimen is the next clinical step.

Treatment Approach (Partial Overview)

The structured regimen involves adding a steroid-sparing cytotoxic agent alongside prednisone. Among the options considered, one agent is particularly recognised for its established use in sarcoidosis due to its effectiveness and tolerability profile at the doses relevant to this condition. The full selection criteria, sequencing, and dosing details are in the complete protocol.

Instant Access to Structured Evidence-Based Regimens

References

  1. If such a taper is not successful, or there is toxicity from the corticosteroids, one should consider the addition of a steroid-sparing agent, such as methotrexate or azathioprine.
  2. When an inadequate response to corticosteroids is noted, cytotoxic agents are often used.
  3. Methotrexate is one of the most commonly used corticosteroid-sparing therapies for sarcoidosis, due to its effectiveness, low cost and, at the dosages used to treat sarcoidosis, relatively low risk of side effects compared to other cytotoxic agents.
View source ↗